Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Abstract

Drug‐induced mucosal injury (DIMI) in the gastrointestinal tract is important to recognise, partly because cessation of the culprit agent alone may result in resolution of symptoms. An ever‐growing list of medications, including newer immunotherapeutic agents and targeted therapies, can cause gastrointestinal inflammation of varying severity. However, the diagnosis of DIMI is challenging, as a single drug can induce a variety of histopathological patterns of injury including acute colitis, chronic colitis, microscopic colitis, apoptotic colopathy, and ischaemic‐type colitis. An additional consideration is the potential clinical, endoscopic and histological overlap of DIMI with gastrointestinal mucosal injury secondary to other entities such as inflammatory bowel disease (IBD). We discuss DIMI of the gastrointestinal tract with an emphasis on histological patterns that mimic IBD, histological features which may distinguish the two entities, and the diagnostic role and limitations of the pathologist.

De Novo Inflammatory Bowel Disease after Liver Transplantation: Eleven Years' Experience in Shiraz, Iran

“…There were no specific gross or microscopic finding differences between patients with AIH and others who developed colitis after OLT. Possible mechanisms of colon inflammation after OLT include CMV infection and perhaps other infective agents, which can simulate IBD both in clinical and pathologic presentations (17). There is a growing concern that post-transplantation colitis may be caused by colon infection among patients who are undergoing immunosuppression.…”

Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments

“…The main clinical symptoms of IBD are bloody stools, abdominal pain, diarrhea, and weight loss [ 296 ]. The pathological conditions in the chemical agent-induced IBD model in mice or rats are generally characterized by colonic inflammation, weight loss, diarrhea, bloody stools, and colon shortening, which are very similar to the clinical symptoms of human IBD [ 297 ].…”

Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach

“…Patients undergoing immunotherapy may be taking or have previously been treated with chemotherapy or others such as nonsteroidal anti-inflammatory drugs (NSAIDs). 86 These therapies may lead to conditions that absolutely mimic ICI colitis, such as mycophenolate mofetil damage, which can cause erosions and colic ulcers, with histological findings of cryptitis, cryptic abscesses, or enterocyte apoptosis. 87 A complete analysis of the drug history and temporal association with the symptoms is essential in these cases.…”